癌症导向手术对转移性头颈癌的生存获益
本研究基于SEER数据库纳入3215例转移性头颈癌(M1 HNC)患者,按是否接受癌症导向手术(CDS)分组,经倾向评分匹配后比较生存。匹配队列中CDS组中位总生存(OS)19.0个月 vs 非CDS组9.0个月(p < 0.001),中位癌症特异性生存(CSS)21.0个月 vs 9.0个月(p < 0.001),多因素Cox回归显示CDS为OS和CSS的有利预后因素。
要点
- 匹配队列中CDS组中位OS 19.0个月 vs 非CDS组9.0个月(p < 0.001)。
- 匹配队列中CDS组中位CSS 21.0个月 vs 非CDS组9.0个月(p < 0.001)。
- 较年轻、已婚、I-II级、口咽部位、较早T/N分期及接受放疗者更倾向从CDS获益,接受化疗者未获益。
核心结论
- 本研究表明CDS与M1 HNC患者生存改善相关,尤其对从CDS获益更多的亚群。
研究设计与样本
- 在SEER数据库中识别M1 HNC患者,按是否接受CDS分为CDS组和非CDS组,使用倾向评分匹配(PSM)最小化两组间偏倚,采用Kaplan-Meier分析、log-rank检验和Cox比例风险模型评估CDS的预后作用,主要终点为总生存(OS),次要终点为癌症特异性生存(CSS)。
- 共提取3215例M1 HNC患者,其中566例接受CDS,并与未接受CDS的患者进行1:1倾向评分匹配。
主要发现
- 匹配数据集中,CDS组中位OS为19.0个月 vs 非CDS组9.0个月(p < 0.001),CDS组显著高于非CDS组。
- 匹配数据集中,CDS组中位CSS为21.0个月 vs 非CDS组9.0个月(p < 0.001),CDS组显著高于非CDS组。
- 多因素Cox回归分析显示CDS为OS和CSS的有利预后因素。
- 亚组分析显示较年轻、已婚、I-II级、口咽部位、较早T/N分期或接受放疗的M1 HNC患者倾向于从CDS获益,而接受化疗的患者未能从CDS获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study aimed to gather evidence for the survival benefit of cancer-directed surgery (CDS) in metastatic head and neck cancer (M1 HNC) and identify which patients will benefit most from CDS. METHODS: Patients with M1 HNC were identified within the SEER database. According to whether received CDS, patients were divided into the CDS and non-CDS groups. The bias between the two groups was minimized using Propensity Score Matching (PSM), and the prognostic role of CDS was investigated using Kaplan-Meier analysis, log-rank test, and Cox proportional hazard models. The primary endpoint was overall survival (OS), and the secondary endpoint was cancer-specific survival (CSS). RESULTS: A total of 3215 patients with M1 HNC were extracted, including 566 patients who received CDS that were 1:1 propensity score-matched with patients who did not receive CDS. In the matched dataset, the median OS and CSS in CDS groups were significantly higher than in non-CDS groups (OS: 19.0 vs. 9.0 months, p < 0.001; CSS: 21.0 vs. 9.0 months, p < 0.001). Meanwhile, multivariable Cox regression analysis also revealed that CDS was a favorable prognostic factor for both OS and CSS. Furthermore, subgroups of patients with M1 HNC (younger age, being married, grade I-II, oropharynx site, earlier T/N stage, radiotherapy) were inclined to benefit from CDS, while those patients who received chemotherapy failed to benefit from CDS. CONCLUSIONS: This study indicated that CDS was associated with improved survival in M1 HNC, especially for those subpopulations that benefit more from CDS treatment. LEVEL OF EVIDENCE: 3 Laryngoscope, 134:1288-1298, 2024.
引用
- Zhu R, Zhu H. Survival Benefit from Cancer-Directed Surgery for Metastatic Head and Neck Cancer. Laryngoscope. 2023. PMID: 37658720. doi:10.1002/lary.31019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。